Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRL03 TCR-T cells
- Development stage
- Unknown
- Lead developer
- Biosyngen
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BRL03 TCR-T cells is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Sun Yat-sen University Cancer Center. The therapy consists of patient-derived T cells genetically modified to express a specific T-cell receptor targeting Epstein-Barr virus (EBV) antigens. It is intended for the treatment of EBV-associated malignancies, including nasopharyngeal carcinoma, lung lymphoepithelioma-like carcinoma, and gastric adenocarcinoma. BRL03 is currently undergoing Phase I clinical evaluation to assess its safety, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced EBV-positive solid tumors who have progressed on standard treatments.
- Other names
- BRL03 TCR-T cell injectionBRL-03 TCR-T cell injectionBRL 03 TCR-T cell injection
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on BRL03 TCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRL03 TCR-T cells.